Evaluating antiangiogenesis agents in the clinic: The Eastern Cooperative Oncology Group portfolio of clinical trials

被引：37

作者：

Sparano, JA ^{[1
]}

Gray, R ^{[1
]}

Giantonio, B ^{[1
]}

O'Dwyer, P ^{[1
]}

Comis, RL ^{[1
]}

机构：

[1] Eastern Cooperat Oncol Grp, Philadelphia, PA USA

来源：

CLINICAL CANCER RESEARCH | 2004年 / 10卷 / 04期

关键词：

D O I：

10.1158/1078-0432.CCR-03-0238

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent evidence indicates that treatment with a humanized monoclonal antibody (bevacizumab) directed at vascular endothelial growth factor improves response and survival in metastatic colorectal cancer when added to standard chemotherapy, validating angiogenesis as a therapeutic target. Investigators from the Eastern Cooperative Oncology Group (ECOG) have initiated a number of Phase III studies that will help further define the role of antiangiogenic agents for the treatment of breast, colon, lung, renal, and head and neck cancer, as well as melanoma and myeloma. The agents being evaluated target various biological functions involved in angiogenesis, including vascular endothelial growth factor (bevacizumab), endothelial cell proliferation (thalidomide, IFN-alpha), and matrix metalloproteinases (marimastat). These clinical trials include correlative laboratory studies aimed at elucidating how these agents may exert their clinical effects. The portfolio of Eastern Cooperative Oncology Group studies will serve to further define the role of this therapeutic strategy for patients with advanced cancer.

引用

页码：1206 / 1211

页数：6

共 54 条

[1] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].